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Background: Multiple sclerosis is an immune-mediated inﬂammatory disease of central nervous system.
MicroRNAs play important roles in autoimmune diseases such as MS.
Objectives: The aim was to evaluate the expression pattern of miR-34a, miR-199a, miR-30c and miR-19a in
peripheral blood derived CD4+ T lymphocytes of both relapsing and remitting phases of MS.
Methods: Blood samples from 40 RRMS patients (20 in relapsing and 20 in remitting phase) and 20 healthy
volunteers were taken. CD4+ T cells were isolated. The expression level of miR-34a, miR-199a, miR-30c and
miR-19a, and the percentage of Th17 and Treg cells were measured. Expression of master transcription factors of
Th17 and Treg cells and several targets of these miRNAs were also evaluated.
Results: Data indicated an increased expression of miR-34a, miR-30c and miR-19a in relapsing phase and de-
creased expression of miR-199a in remitting phase. ROC curve data add other prestigious information of miR-
34a, miR-199a, miR-30c and miR-19a by deﬁning relapsing and remitting phase and also healthy cases with high
speciﬁcity and sensitivity at a proposed optimum cut-oﬀ point.
Conclusion: Collectively, we showed a correlation between the four miRNAs with diﬀerent phases of MS and
their possible involvement in diﬀerentiation pathways of Th17 cells, as the most important players in MS.
1. Introduction
Multiple sclerosis (MS), also known as disseminated sclerosis or
encephalomyelitis disseminate, is an inﬂammatory autoimmune disease
which severely aﬀects people globally. MS disease onset normally oc-
curs in young adults, and like other autoimmune diseases, it is more
common in women rather than men (Milo and Kahana, 2010;
Etemadifar et al., 2014). As a result of this disease, the insulating covers
of nerve cells in the brain and spinal cord are damaged.
Epidemiologic studies of MS in Isfahan province of Iran, indicates
that there is a harsh growth in the frequency of aﬀected patients with
an overall prevalence of 85.8 in 105 (Etemadifar et al., 2014). MS is
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considered as a multi-factorial disease, and it is still unclear that how
the disease initiates and becomes chronic. The underlying mechanism is
supposed to be either destruction by the immune system or failure of
the myelin-producing cells. Possible causes for this include genetics and
environmental factors such as infections (Milo and Kahana, 2010). It
has been proven that T-cell-mediated inﬂammation is critical in the
pathogenesis of MS (Lassmann, 2006; Bendszus and Storch-
Hagenlocher, 2013). It is now believed that Th17 cells essentially exert
their eﬀects via secreting IL-21, IL-22, IL-17 and GM-CSF, which are
necessary for autoimmune neuro-inﬂammation. In the presence of TGF-
β, IL-1β and IL-23, and following the activation of speciﬁc transcription
factors of RORγt/STAT3, naïve CD4+ T cells diﬀerentiate into Th17
subset (Kebir et al., 2007; Zhu and Paul, 2010; Hakemi et al., 2011).
Similar to the other autoimmune diseases, MS is neatly related to de-
ﬁciencies in immune regulation through suppression of regulatory T
cells (Treg) (Kebir et al., 2007) as their diﬀerentiation occurs through
activation of STAT5/Foxp3 (Bartel, 2009).
MicroRNAs (miRNAs) are a set of small non-coding RNAs that bind
to 3′ UTR region of their target mRNAs and can either repress trans-
lation or induce mRNAs degradation (Bartel, 2009). Plenty of studies
have shown that posttranscriptional regulation by miRNAs is an im-
portant procedure in diﬀerentiation pathways and in a lot of other
biological processes (Baltimore et al., 2008; Liu et al., 2010). For ex-
ample, miRNAs possess vital roles in haematopoiesis and functions of
immune cells including T cells (Baltimore et al., 2008; Zibert et al.,
2010). Mir-34 precursor family set grounds for production of three
major mature miRNAs in mammals. These family members are located
on chromosome 1 and 11 (Hermeking, 2010). The precursor miRNA
stem-loop is processed in the cytoplasm of the cell, and the pre-
dominant miR-34 mature sequence is excised from the 5′ arm of the
hairpin (Mráz et al., 2009). Meanwhile, miR-199 is related to miR-214
and both miRNAs are transcribed together in the form of a common
family (Loebel et al., 2005). The miR-199 family is located on chro-
mosomes 19 and 1 (Chen et al., 2008). MiR-199a/214 cluster genes are
encoded by the DNM30s (Dynamin 3 opposite strand). MiR-30c in
humans and vertebrate cells plays an important role in intracellular
functions (Lagos-Quintana et al., 2001). The miR-30c locus is found on
chromosome 6 and 1 (Weber, 2005). Pre-construction products of miR-
30 have a regulatory eﬀect on a number of mRNAs. The cluster of miR-
17-92, codes 6 mature miRNAs that one of them is miRNA-19 family
(Ambros, 2001). MiR-19a family has been identiﬁed in vertebrates and
consists of 89 diﬀerent sequences, and is located on chromosome 13 in
human. This is involved in the regulation of gene expression (Houbaviy
et al., 2003).
Various studies on miR-34a, miR-199a, miR-30c and miR-19a show
that these miRNAs are involved in diﬀerent autoimmune diseases and
cancers. Studies on inﬂammatory bowel disease (IBD), psoriasis, rheu-
matoid arthritis (RA) and other immune-related diseases have revealed
deregulation of miR-34a, miR-199a, miR-30c and miR-19a in patients
versus healthy groups (Chen et al., 2007; Iborra et al., 2013; Zibert
et al., 2010). For example, miR-30c was reduced in samples taken from
superﬁcial skin lesions of patients with Psoriasis (Sonkoly et al., 2007)
and had impaired regulation in biopsies of patients with IBD (Fasseu
et al., 2010) and in the plasma samples of RA patients (Murata et al.,
2013). Biopsy samples from patients with the impaired regulation of
miR-19a also indicate that this set of genes get involved in development
of autoimmune and lymphoproliferative disorders in rats, and lupus-
like autoimmunity (Rigby and Vinuesa, 2008; Xiao et al., 2008). In one
study, regulation of miR-19a was impaired in biopsy specimens from
patients with IBD (Iborra et al., 2013). Hence, these microRNAs may
have similar immunopathogenic roles in MS.
The most important players in immunopathogenesis of many auto-
immune diseases like MS are Th17 cells. The miR-34a, miR-199a, miR-
30c and miR-19a might have a role in diﬀerentiation of Th17 cells.
Thus, their deregulation could be consistent with the increase or de-
crease the number of Th17 cells during relapsing and remitting phases
of MS.
The aim of the current study was to evaluate miR-34a, miR-199a,
miR-30c and miR-19a expression levels in CD4+ T cells of relapsing
versus remitting phase of MS patients. Through this, we tried to pin-
point the miRNAs potential role in diﬀerentiation or suppression of
Treg or Th17 cells via assessing their correlation in diﬀerent phases of
MS. Moreover, possible targets of miR-34a, miR-199a, miR-30c and
miR-19a that could be considered to be involved in diﬀerentiation of T
helper cells were established in-silico, and their accuracy was studied in
vitro.
2. Materials and methods
2.1. Patients and control samples
Informed consent was obtained for experimentation with human
subjects before sampling. This study was approved by the Institutional
Medical Ethics Committee of Royan Institute, Tehran, Iran. All clinical
information of patients including age, sex, disease duration and MRI
results are summarized in Supplementary Table 1. Ten mL blood sam-
ples (with EDTA) were collected from 20 patients with relapsing and 20
with remitting MS had been referred to Hasht-behesht Policlinic in
Isfahan. Sampling was done when the patients were newly diagnosed
(as relapsing phase) and one week after their ﬁrst injection, just before
they receive their second dose of medication, (as remitting phase).
Moreover, 20 control blood samples were obtained from healthy vo-
lunteers. Patients were diagnosed based on Mc-Donald criteria in MS by
a neurologist.
2.2. Cell isolation
Peripheral blood mononuclear cells (PBMCs) were isolated using
density gradient Lymphoprep (STEMCELL Technologies, USA) ac-
cording to the manufacturer's instructions. CD4+ T cells sub-population
were isolated from PBMCs using human CD4+ T cells isolation kit II
(Germany, Miltenyi Biotec) according to the manufacturer's instruc-
tions.
2.3. Flow cytometry analysis of T cells
Cells were analyzed for FOXP3, RORγt and CD4 expression using
ﬂow cytometry method. Isolated cells were stained with Anti-Human/
Mouse RORγ (t)-PE, Anti-Human Foxp3-PE, Anti-Human CD3 FITC and
Anti-Human CD4-Alexa Fluor 488 (eBioscience, USA) antibodies and
were analyzed with Becton Dickinson ﬂow cytometer (FACSCalibur,
USA) using Cell Quest Pro software. Then, the data were analyzed
versus Mouse IgG1 K isotype Control-PE, Rat IgG2a K isotype Control-
PE, Mouse IgG2b K isotype Control-Alexa Fluor 488 (eBioscience) and
unstained cells.
2.4. Gene expression evaluation with real-time PCR
Total RNA (including miRNAs) was isolated using TRizol reagent
(Invitrogen, USA) based on the manufacturer's instruction. The cDNA
synthesis for miR-34a, miR-199a, miR-30c and miR-19a was performed
with a “universal cDNA synthesis kit” (Exiqon, Denmark) using a poly-A
tailing method, as stated by manufacturer. Quantitative real-time PCR
(Q-PCR) reactions were performed using standard protocols in an ABI
PRISM 7500 instrument (Applied Biosystems, USA). Brieﬂy, in a total
volume of 10 μL, 20 ng/μL of cDNA products were added to a master
mix comprising 10 pmol/μL of the miRNAs pre-designed primers
(Exeqon, Denmark) and 2 U of SYBR premix ExTaq II (TaKaRa, Japan).
The run method program was set at 95 °C for 5min followed by
40 cycles of 95 °C for 5 s,60 °C for 20 s and 72 °C for 30 s. RNU48, small
nucleolar RNA, was quantiﬁed as a control to normalize the results.
Synthesis of cDNA for RORC2, TGF-β, IL-17A and FOXP3 on total RNA
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was carried out using Revert Aid First Strand cDNA synthesis Kit
(Fermentas, Lithuania) using random hexamer primers. Q-PCR was
performed using speciﬁc pre-designed primer pairs in ABI PRISM 7500
instrument (Applied Biosystems, USA). The run method program was
set at 95 °C for 5min followed by 40 cycles of 95 °C for 5 s, 60 °C for 20 s
and 72 °C for 30 s. Expression levels of these genes were normalized
against 18srRNA as the reference gene. All reactions were carried out in
triplicate. Data were evaluated and reported based on relative quanti-
ﬁcation method (Ma et al., 2014).
2.5. Poly acrylamide gel & T/A cloning
To specify the miR-34a, miR-199a, miR-30c and miR-19a primers,
Q-PCR products were run on 12% polyacrylamide gel to see solo band
with approximate size of 80 bp (data not shown). Samples were diluted
in sample buﬀer (Tris-HCl 0.5 mM, pH: 6.8, 20%glycerol, 0.025% blue
bromophenol) and were loaded on poly acrylamide gel. Product bands
were observed as the sole bands of Q-PCR. To further conﬁrm this re-
sult, T/A cloning was performed. Brieﬂy, Q-PCR products were cloned
into pTZ57R/T (Fermentas, Lithuania) and transformed into competent
E. coli cells. After selection of the appropriate recombinant colonies,
plasmid preparation was performed and one clone of each miRNA was
selected for sequencing.
2.6. Molecular signalling pathway enrichment analysis
In order to accomplish molecular enrichment analysis on miR-34a,
miR-199a, miR-30c and miR-19a targetome and to ﬁnd the most related
signalling pathways that might be involved, we used online in-silico
databases like miRWalk (http://zmf.umm.uni-heidelberg.de/apps/zmf/
mirwalk2/) (Dweep et al., 2011) and miRTarBase (http://mirtarbase.
mbc.nctu.edu.tw/php/index.phpA) (Hsu et al., 2010) to attain pre-
dicted and validated targets of miR-34a, miR-199a, miR-30c and miR-
19a. We also used DIANA miRPath v.2.0 (http://diana.imis.athena-
innovation.gr/DianaTools/index.php?r=mirpath/index) (Vlachos
et al., 2012) to visualize pathways of validated targets of miR-34a, miR-
199a, miR-30c and miR-19a as a heat map. Then, using UniGene da-
tabase (http://www.ncbi.nlm.nih.gov/unigene/) and subsequent EST
proﬁling, we studied their expression in lymph nodes and thymus since
it will be indispensable if they are involved in diﬀerentiation of T helper
cells. Finally, miR-34a, miR-199a, miR-30c and miR-19a targetome
expressed in lymph nodes and thymus were assigned to DAVID bioin-
formatics database (https://david.ncifcrf.gov/) (Delgoﬀe et al., 2011),
to categorize the most applicable pathways and molecular networks.
The signalling pathways analyzed were:
1. JAK/STAT signalling pathway and the eﬀects of miR-34a, miR-199a
and miR-30c on it (DAVID; Fig. 1).
2. MTOR signalling pathway and the eﬀects of miR-34a and miR-19a
on it (DAVID, Fig. 2).
3. TGF-β signalling pathway and the eﬀects of miR-34a, miR-30c and
miR-19a on it (DAVID, Fig. 3).
2.7. Statistical analysis
All statistical tests were performed using SPSS 20 (Chicago, IL,
USA). Comparison between groups was carried out using one way
ANOVA test. Data are presented as mean ± SEM and considered sig-
niﬁcant at p < 0.05. In order to measure and achieve the potential of
miR-34a, miR-199a, miR-30c and miR-19a as diagnosis accurate factors
of diseases to distinguish MS relapsing and remitting phases and
healthy persons, receiver operating characteristic (ROC) curves were
performed and the area under the curve (AUC) was gauged by calcu-
lating sensitivity and speciﬁcity for each possible cut-oﬀ point of the
miR-34a, miR-199a, miR-30c and miR-19a expression level. The p value
0.05 was considered as statistical signiﬁcance for all tests.
3. Results
3.1. The number of Th17 cells increased signiﬁcantly in relapsing phase,
while Treg cells increased in remission phase of MS
At the ﬁrst stage, we evaluated the number of Th17 and Treg cells in
diﬀerent phases of MS. Results have revealed that the percentage of
RORC2+ CD4+ T cells was signiﬁcantly increased in relapsing group as
compared to the remitting and the healthy group as controls
(p= 0.0002, p=0.0003, respectively), while the remitting phase pa-
tients displayed a signiﬁcant increase in the percentage of Foxp3+
CD4+ T cells compared to the patients in the relapsing (p=0.003) and
healthy controls (p= 0.001) (Fig. 4).
3.2. Expression of master transcription factors involved in Th17/Treg
diﬀerentiation along with IL-17A gene expression in CD4+ T cells
To conﬁrm the results of ﬂow cytometry, we analyzed whether the
expression level of master markers of Th17 and Treg cells have changed
during the course of the disease from relapsing to remitting. Expression
level of IL-17A was signiﬁcantly increased in relapsing phase compared
to remitting phase (p=0.023). Analysis of RORC expression demon-
strated a signiﬁcant rise in relapsing group compared to both remitting
and control groups (p= 0.0007 and p=0.002, respectively). TGF-β
expression level showed a signiﬁcant increase in relapsing versus con-
trol group (p= 0.008). However, it was also up regulated in remitting
group versus control group (p=0.029). Finally, the expression level of
Fig. 1. The miR-34a, miR-199a, miR-30c and miR-19a targetome has joint several important pathways including TGF-β, JAK/STAT and mTORC. Their partial diagram is demonstrated
which selected from KEGG pathway. JAK/STAT pathway is a joint one for miR-34a, miR-199a and miR-30c. The targets of these mRNAs are SOCS and STAT5.
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Foxp3 was signiﬁcantly decreased in relapsing compared to control
group (p= 0.046).
3.3. Up-regulation of miR-34a, miR-30c, miR-19a and down-regulation of
miR-199a in relapsing phase of MS
The expression level of miR-34a was signiﬁcantly higher in relap-
sing group compared to control and remitting groups (p= 0.043 and
p=0.031, respectively). Nevertheless, no meaningful diﬀerence was
Fig. 2. The mTORC pathway is introduced as a joint pathway between miR-34a and miR-19a. The targets of these mRNA are Tsc1, mTOR and PTEN, as indicated with red stars. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 3. TGF-β pathway is selected as another pathway for each miR34a, miR-30 and miR-19a. The targets of these mRNAs are TGF-βR1, SMAD2, 3 and 4, as indicated with red stars. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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observed between control and remitting groups (p=0.874) (Fig. 5A).
Expression pattern of miR-199a was opposite to miR-34a expres-
sion. MiR-199a expression level elevated signiﬁcantly in remitting
group versus control and relapsing group (p=0.043 and p=0.044,
respectively). There was also no signiﬁcant diﬀerence between control
and relapsing group (p= 0.644) (Fig. 5B).
The expression level of miR-30c was more in relapsing group
compared to remitting group and healthy controls (p= 0.014 and
p=0.049, respectively). Nevertheless, there were no meaningful dif-
ferences between remitting patients and control individuals
(p= 0.860) (Fig. 5C).
Transcript level of miR-19a was signiﬁcantly elevated in relapsing
group versus remitting group (p= 0.008) but there was no meaningful
diﬀerence between healthy volunteers and both remitting and relapsing
patients (p= 0.550 and p=0.186, respectively) (Fig. 5D).
3.4. The potentials of miR-34a, miR-199a, miR-30c and miR-19a as
discriminating biomarkers
We compared expression level of miR-34a, miR-199a, miR-30c and
Fig. 4. Flow cytometric analysis of FoxP3+ CD4+ T cells
and RORC2+ CD4+ T cells. CD4+ T cells were isolated
with human CD4+ T cell isolation kit II and stained with
respective antibodies and evaluated in relapsing and re-
mitting phases of MS patients and in healthy controls. (a:
Relapsing patients (n=20), b: remitting patients (n= 20),
c: healthy volunteers (n=20).) (A) Percentage of RORγt
+CD4+ T cells shows meaningful increase in relapsing
group (B) while percentage of FoxP3+ CD4+ T cells were
elevated in remitting group (*p < 0.05, **p < 0.01 and
***p < 0.005).
Fig. 5. Up-regulation of miR-34a, miR-30c, miR-19a and down regulation of miR-199a in relapsing phase of MS patients. (A) Expression level of miR-34a in CD4+ T cells of MS patients in
relapsing phase (n= 20), remitting phase (n= 20) and healthy controls (n= 20). (B) Expression level of miR-199a in CD4+ T cells of MS patients in the same groups. (C) Expression level
of miR-30c in CD4+ T cells of MS patients in relapsing phase. (D) Expression level of miR-19a in CD4+ T cells of MS patients is as the same. Results are normalized versus RNU48 as
reference gene (*p < 0.05, **p < 0.01 and ***p < 0.005).
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miR-19a in CD4+ T cells from the three groups by ROC analysis to
recognize the potentials of miR-34a, miR-199a, miR-30c and miR-19a
expression level as diagnostic biomarkers for distinguishing among
relapsing, remitting and healthy conditions. ROC data characterized the
optimal relative expression level cut-oﬀ value of 0.13 for miR-34a, 1.65
for miR-30c and 6.11 for miR-19a to identify the remitting and relap-
sing phases in RR-MS patients (Fig. 6A, B and C, respectively). The
optimal relative expression level cut-oﬀ values were 0.19 for miR-199a,
3.12 for miR-30c and 0.53 for miR-34a to distinguish the MS patients
from healthy persons (Fig. 6D, E and F, respectively). This analysing
also demonstrated sensitivity, speciﬁcity and area under the ROC curve
of all of the studied miRNAs (Table 1).
3.5. Molecular signalling pathway enrichment analysis of miR-34a, miR-
199a, miR-30c and miR-19a targetome proposes possible role of miR-34a,
miR-199a, miR-30c and miR-19a in diﬀerentiation of Th17 cells
To recognize the potential role of miR-34a, miR-199a, miR-30c and
miR-19a in Th17 diﬀerentiation, molecular signalling pathway en-
richment analysis was conducted as described in Materials and methods
section. Using miRWalk and miRTarBase databases, for miR-199a,
14,153 predicted and 40 validated mRNA targets were found.
Moreover, for miR-34a, 13,547 predicted and 525 validated mRNAs
targets were speciﬁed. In addition, 8192 predicted and 242 validated
mRNAs for miR-30c and 3897 predicted and 41 validated mRNAs for
miR-19a were speciﬁed (data not shown). All predicted targets in
MiRWalk were conﬁrmed through at least ﬁve predictor databases.
Additionally, all validated mRNA targets collected from miRTarBase
had been supported by experimental evidences. Heat map view of va-
lidated targets designed by DIANA miRPath v.2.0 showed that the
pathways involved in diﬀerentiation of Th17 cells, which miR-34a,
miR-199a, miR-30c and miR-19aa might inﬂuence them, are mTOR
signalling pathway and TGF-β signalling pathway. These mRNAs aﬀect
SOCS, STAT5 expression, as the negative regulators of Th17 pathway
(Xiao et al., 2008; Edwards et al., 2011).
Fig. 6. ROC curve of RR-MS sample sets (relapsing, remitting patients and healthy volunteers) analyzed for relative expression level of miR-34a, miR-199a, miR-30c and miR-19a in
CD4+ T cells. These analyses indicated the optimal relative expression level cut oﬀ value of 0.13 for miR-34a (A), 1.65 for miR-30c (B) and 6.11 for miR-19a relative (C) to identify
remitting and relapsing RR-MS patients. The sensitivities and speciﬁcities were 82% and 67% for miR-34a (A), 82% and 87% for miR-30c (B), and 84% and 63% for miR-19a (C). The
optimal relative expression level cut-oﬀ values were 0.19 for miR-199a (D) and 3.12 for miR-30c relative expression levels (E) to distinguish the patients from healthy persons with the
sensitivity and speciﬁcity of 94% and 63% (D), and 53% and 100% (E), respectively. At the cut oﬀ value of 0.53 (F), miR-34a can distinguish between patients and healthy group with
sensitivity and speciﬁcity of 46% and 100%, respectively. Areas under the ROC curve of 0.765, 0.875, 0.781, 0.771, 0.778 and 0.714 were respectively belonging to miR-34a, miR-30c,
miR-19a, miR-199a, miR-30c and miR-34a (again), regarding to the criteria explained in the materials and methods.
Table 1
ROC analysis of miR-34a, miR-199a, miR-30c and miR-19a for distinguishing between
relapsing and remitting phases of MS as well as healthy controls.
miRNA Cut oﬀ
value
Sensitivity Speciﬁcity Area under
the curve
Distinguish
between
miR-34a 0.13 82% 67% 0.765 Remit and
relapse
miR-34a 0.53 46% 100% 0.714 MS and healthy
miR-199a 0.19 94% 63% 0.771 MS and healthy
miR-30c 1.65 82% 87% 0.875 Remit and
relapse
miR-30c 3.12 53% 100% 0.778 MS and healthy
miR-19a 6.11 84% 63%0 0.781 Remit and
relapse
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Lastly, validated and predicted genes with deﬁned expression in
lymph node and thymus were chosen for extra molecular enrichment
analysis (not shown in this paper). A combined view of statistically
meaningful pathways associated with above genes in KEGG (http://
www.genome.jp/kegg/pathway.html), BIOCARTA (http://www.
biocarta.com/), and PANTHER (http://www.pantherdb.org/pathway/
) pathways were acknowledged by inputting oﬃcial gene symbols of
miR-34a, miR-199a, miR-30c and miR-19a targetome into the func-
tional annotation tool of DAVID. MiR-199a targetome was commonly
enriched in cancer and JAK/STAT signalling pathways. On the other
hand, miR-34a targetome was recognized in mTOR, TGF-β pathways
and JAK/STAT signalling pathways demonstrating the combined in-
tended schematic KEGG signalling pathways (Supplementary Tables 2
and 3). JAK/STAT signalling pathways, TGF-β pathways, adherent
junction, chronic myeloid leukemia, ALK in cardiac myocytes, some
cancers and etc. were enriched for miR-30c and miR-19a targetome.
The mTORc and JAK/STAT pathways were also selected as other
probable pathways for miR-19a and miR-30c. All miR-30c and miR-19a
common targets are indicated with red stars in Fig. 2. TGF-β was se-
lected as meant pathway for miR-30c and miR-19a (Fig. 3). In mTOR
pathway, miR-34a and miR-19a aﬀect TSC1 and mTOR. These genes are
negative regulators of Th17 diﬀerentiation. In TGF-β pathway, miR-
34a, miR-19a and miR-30c inhibit SMAD2, 3 and 4 genes expression.
These genes are negative regulators of Th17 pathway and cause of
diﬀerentiation to Treg pathway.
4. Discussion
Th17 cells are a subset of CD4+ T cells involving in the defence
against extra cellular bacterial and fungal infections. However, they are
well-known for their roles in pathogenesis of autoimmune diseases like
MS (Tesmer et al., 2008). Therefore, factors that are involved in Th17
cells diﬀerentiation are considered as potential therapeutic targets for T
cell mediated autoimmune diseases.
Our ﬂow cytometric data showed increased frequency of Th17 cells
in relapsing phase while Treg cells were elevated in remission phase. To
conﬁrm the results, the expression level of IL-17A, RORC, TGF-β and
FOXP3 in diﬀerent phases of MS were assessed. Our experiments
showed up-regulation of RORC, and IL-17A in relapsing phase of MS
patients. Thus, elevated frequency of Th17 cells in relapsing phase was
conﬁrmed. The level of FOXP3 expression as a master transcription
factor of Treg cells has been decreased in relapsing phase compared to
healthy controls, whereas there was not a large diﬀerence between
remitting group and healthy volunteers. This means that normal Treg is
necessary to end inﬂammation in relapsing phase. TGF-β was increased
in both relapsing and remitting phases of MS which may be correlated
with its dual role in diﬀerentiation of both Th17 and Treg cells. At high
concentrations, TGF-β promotes FOXP3 expression which leads to Treg
cell generation, while low concentrations of TGF-β stimulates Th17 cell
diﬀerentiation via RORγt and STAT3 expression (Hakemi et al., 2011;
Peters et al., 2011).
In the present study, we evaluated the expression of miR-34a in two
phases of MS (remitting and relapsing) compared with healthy in-
dividuals. The results showed that the expression of miR-34a was sig-
niﬁcantly increased in relapsing phase, in comparison with remitting
and control group.
Previously, it has been reported that miR-34a is up-regulated in
active lesion of MS patients (Junker et al., 2009). This result, along with
ours, conﬁrms the possible involvement of miR-34a in suppression of
Treg formation and deviation towards Th17 development. The miR-34a
inﬂuences some target genes such as STAT3, Foxp3 and TGF-β that their
involvement in diﬀerentiation to Th17 cells was predicted in the cur-
rent study using miRTarBase database. Elevation of STAT3 expression
in MS patients has previously been reported (Chung et al., 1997; Chen
et al., 2007). SOCS3 can inhibit STAT3 that is necessary for diﬀer-
entiation of Th17 cells (Chen et al., 2006). Up-regulation of miR-34a
could result in decrease of SOCS3 which leads to increase of STAT3 and
elevation of Th17 cells in MS patients. Foxp3, involved in Treg sig-
nalling pathway, is another predicted target of miR-34a. Therefore, the
more miR-34a expresses the less Treg will generate; as we observed in
the present study. Some studies have reported reduced levels of TGF-β
in CD4+T cells of MS patients (Acosta-Rodriguez et al., 2007; Lee et al.,
2009). Surprisingly, we observed elevated transcript levels of TGF-β1
both in relapsing and remitting phases. However, as TGF-β1 is im-
portant for diﬀerentiation of both Th17 and Treg cells in a dose de-
pendent manner (Hakemi et al., 2011), these contradictory results
could be addressed.
On the other hand, one group has reported that the expression of
miR-34a in CD4+ T cells is decreased in patients with RR-MS (Lindberg
et al., 2010). As they didn't specify the phase of illness at the time of
sampling, this discrepancy might be due to the fact that the evaluation
was presumably performed in remitting phase rather than relapsing.
Among the other predicted targets of miR-34a, RUNX3 and RORC
are involved in Th17 diﬀerentiation pathway (Klunker et al., 2009a;
Hakemi et al., 2011). Hence, decreasing of Th17 speciﬁc markers could
be assumed when miR-34a is elevated in relapsing phase. Nevertheless,
this was not happened in the current study. As these targets have not
yet been experimentally validated for miR-34a, this conclusion is not
necessarily correct.
Also we measured the expression of miR-199a in this study. We
showed that the expression of miR-199a was not only signiﬁcantly in-
creased in remitting phase compare to relapsing phase and controls, but
also highly reduced in relapsing phase. Simultaneously, the frequency
of Treg cells was also highly elevated in the remitting group. In one
study, the expression level of miR-199a found to be dramatically de-
creased in the PBMCs from patient with MS compared with control
group (Ma et al., 2014). Another study has reported that this miRNA is
up-regulated in active brain white matter lesions of MS patients
(Munoz-Culla et al., 2013). Elevation of miR-199a expression has been
shown the in some autoimmune diseases such as atopic eczema (AE)
and systematic lupus erythematosus (SLE) (Dai et al., 2007). In EAE
(the experimental model of MS), high level of miR-199a was observed
(Bergman et al., 2013). These results are contradictory and could not be
compared with ours as the phase of illness at the time of sampling is not
speciﬁed. However, its increase in SLE and AE in which Th17 cells are
not the main players, could be consistent with our results in remitting
phase.
In one study, the researchers have found that miR-199a by sup-
pressing HIF1α and SIRT1, may play a role in Treg cell diﬀerentiation
(Rane et al., 2009; Rane et al., 2010). This could be correlated with our
ﬁndings. Thus, one can conclude that miR-199a can inhibit some genes
involving in Th17 diﬀerentiation while activate some other genes that
are crucial in Treg development.
We showed that the expression of RORγt, a predicted target for miR-
199a, was signiﬁcantly higher in relapsing phase versus remitting phase
and healthy controls. RORγt is lineage speciﬁc transcription factor for
Th17 diﬀerentiation. Thus, up-regulation of miR-199a must be corre-
lated with less frequent Th17 cells and lower expression of RORγt in
remitting phase, as we showed in the current study.
Also, our results showed a signiﬁcant increase in expression of miR-
30c in patients CD4+ T cells with relapsing phase. A relatively little
reduction was observed in expression of miR-30c in remitting patients
in compared with healthy controls. In one study by Jarnas M. et al.,
reduction of miR-30c expression in peripheral blood T cells in RRMS
patients was shown (Jernås et al., 2013). Rejerkerk A. et al. in another
study also showed that the expression of miR-30c is reduced in lesional
capillaries in patients with MS (Reijerkerk et al., 2013). These seem to
be contrary with our ﬁndings, however, as they have not deﬁned the
phase of the illness in the time of sampling, their results might re-
presents the situation exists in remitting phase. As we also ﬁnd miR-30c
reduction in remitting phase, these results may be consistent with ours
in this aspect. Moreover, the samples have been used in those studies
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were diﬀerent from ours (PBMC, brain tissue versus CD4+ T cells).
We also showed a signiﬁcant elevation of miR-19a expression in MS
patients with relapsing phase. Similar to miR-30c, a little decrease in
the level of miR-19a in remitting phase of MS patients in compared with
healthy controls was observed. Menaka C.et al. introduced miR-19a as a
miRNA that plays a critical role in CNS function and diseases of the
nervous system damage (Thounaojam et al., 2013). This is consistent
with our ﬁndings. De Santis et al. and Raija L P et al. separately have
shown that miR-19a expression had no diﬀerences in CD4+ T cell
between RRMS patients and healthy volunteers (De Santis et al., 2010;
Lindberg et al., 2010). This is not correlated with our results; however,
as they didn't specify the phase of the disease at the time of sampling,
this could not be necessarily controversial. In addition, Paraboschi et al.
showed increased level of miR-19a in PBMC of patients with MS in
remission phase (Paraboschi et al., 2011) which is contrary with our
ﬁndings. However, this may be related to diﬀerent studied samples
(PBMC vs. CD4+ T cells).
According to our bioinformatics surveys, miR-30c and miR-19a
target several important negative regulators of Th17 diﬀerentiation
pathway such as SMAD2, SMAD4, TGFβR2, SOCS3, FOXO3 and TSC1.
ETS1, BCL6 and STAT1 are speciﬁc targets for miR-30c and STAT5B,
RUNX3, TGF-β1 and PTEN are targets for miR-19a. We nominate
mTORC and JAK/STAT pathways which are aﬀected by miR-19a and
miR-30c, respectively. TSC1and PTEN are negative regulators for Th17
diﬀerentiation by mTORC pathway (Sauer et al., 2008; Park et al.,
2013). ETS1 is an negative regulator for IL-2 and STAT5 signalling
pathway (Moisan et al., 2007). STAT1 and STAT5B are also predicted as
Th17 inhibitors. STAT5B is a important protein in Treg diﬀerentiation
(Ivanov et al., 2007; Laurence et al., 2007). One of the recent studies
estimated the BCL6 as a target protein of miR-30c which cause a ne-
gative impression of Th17 diﬀerentiation (Honardoost et al., 2015). It
was also shown that BCL6 protein can repress RORγt expression in CD4
T cells and inhibit Th17 diﬀerentiation (Yu et al., 2009). SOCS proteins
are the strongest negative regulators in STAT pathways (Krebs and
Hilton, 2001). For example, speciﬁc deletion of SOCS3 increases STAT3
phosphorylation and IL-17 production (Alexander and Hilton, 2004).
FOXO proteins are important factors in diﬀerentiation of Treg cells from
naïve T cells through binding to FOXP3 promotor (Zhu and Paul, 2010).
RUNX3 play as one of the important proteins which induce Treg cells
generation (Klunker et al., 2009b). SMAD2, SMAD4 and TGFβR2 are
also some downstream targets in TGF-β pathway (Breitkopf et al.,
2006). Our investigations suggest that TGF-β pathway is probably af-
fected by both miR-30c and miR-19a. As mentioned before, we wit-
nessed increasing of TGF-β in both relapsing and remitting phases.
Nonetheless, due to the increased expression of miR-19a and miR-30c
in relapsing phase, it seems that the expression level of TGF-β down-
stream signalling molecules like SMAD2, SMAD4, TGFβR2 might be
decreased in relapsing phase, leading to reduction of Treg cells fre-
quency similar to our previous report (Naghavian et al., 2015). Ac-
cording to our data which conﬁrm Th17 up-regulation in relapsing and
Treg up-regulation in remitting phase, it could be suggested that in-
creased expression of miR-30c and miR-19a in relapsing phase might
suppresses all these Th17 negative regulators and hence, promotes
diﬀerentiation towards Th17 cells.
We found that increasing of Th17 cells and decreasing of Treg cells
frequency in relapsing phase is correlated with reduction of FOXP3
elevation of RORC, IL-17A and IL-23R. This is also correlated with
elevation of miR-30c and miR-19a in the same phase. Based on these
ﬁndings and the fact that these miRNAs target a number of genes af-
fecting Th17/Treg ratio, we can conclude that these targets (as FOXO3,
SOCS3, TSC1) could be suppressed by miR-30c and miR-19a in relap-
sing phase leading to elevation of Th17 cells. However, this should be
proved with more experiments.
Finally, ROC analysis demonstrated a high and reliable ability for
miR-34a, miR-30c, miR-19a and miR-199a as potential biomarkers with
high sensitivity and speciﬁcity for distinguishing between relapsing and
remitting phases of RR-MS as well as between illness and healthy
condition in this disease. However, it is obvious that more studies in
larger scales are needed to conﬁrm this expression for clinical use of
miR-34a, miR-199a, miR-30c and miR-199a as diagnosis biomarkers for
relapsing period from remitting in RR-MS patients.
5. Conclusion
In the present study, we showed up-regulation of miR-34a, miR-30c,
miR-19a and down-regulation of miR-199a in relapsing phase of MS
which was correlated with more frequent Th17 cells in the same phase
of the illness and severity of the disease. In other word, these miRNAs
are diﬀerentially involved in Th17 and Treg cells development and
hence, inﬂuence the disease manifestations. Therefore, miR-34a, miR-
199a, miR-30c and miR-19a could now be used as biomarkers for
monitoring the relapsing and remitting phases of MS in molecular level
and maybe as potential therapeutic targets at near future.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.gene.2018.03.035.
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